The health economics of XXXX and @entity3875 for the prevention of @entity173 in Sweden.

@entity1 @entity3875 @entity170 @entity173 @entity460
OBJECTIVE: The objective of this study was to examine the economics of administering @entity460 and @entity3875 to post-menopausal @entity1 in Sweden. We focus primarily on the cost-effectiveness of treating older @entity1 for whom clear evidence of efficacy is available. We supplement this information, however, with estimates of the cost-effectiveness of treating certain high-risk groups of younger @entity1 , while acknowledging the greater uncertainty involved. METHODS: We developed a Markov model for analyzing the occurrence and timing of @entity173 , based almost entirely on peer-reviewed data from Sweden. In a 3-year randomized clinical trial, the combination of @entity460 and @entity3875 was shown to reduce the risk of @entity173 by 27%. Costs for treating @entity173 were based on 1,080 @entity1 who were hospitalized in Stockholm. RESULTS: Treatment of 70-year-old @entity1 was cost saving at efficacy as low as two-thirds that seen in the clinical trials, and upwards. Even at modest rates of efficacy, treatment of the high-risk 50- and 60-year-old cohorts was generally cost-effective and in some cases even cost saving. Particularly cost-effective was treatment of @entity1 with identified @entity170 or a maternal family history of @entity173 . CONCLUSION: Simulation results suggest a role for lifetime treatment of older @entity1 with @entity460 and @entity3875 in Sweden. While there is more uncertainty underlying the treatment of younger @entity1 , our simulation results suggest that treatment may also be cost saving or at least cost-effective for many cohorts of high-risk 50- and particularly 60-year-old @entity1 , in particular those with @entity170 or a maternal family history of @entity173 .
